IRAK4 and diffuse large B-cell lymphoma: ND2158 has been described as a highly selective and bioavailable small molecule IRAK4 inhibitor, which exhibited robust activity against the ABC subtype of DLBCL presenting with MYD88 mutations in preclinical mouse models [16].